Cencora

McKesson

Cardinal Health

Walgreens Boots Alliance

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 SteadyMD is a telehealth platform for users to connect with doctors any time via text, phone, and video chats. The platform attempts to enable a long-term relationship between the patients and their consultants by making it easier for patients to contact doctors via text messaging whenever they need advice. SteadyMD claims that it has less than 600 patients per doctor, which is significantly lower than 2,500 a traditional primary care doctor has. Its matching engine evaluates new members with healthcare providers across hundreds of medical, fitness, and lifestyle attributes to help build a long-term connection. Pricing for an individual is USD 99 per month for a 12-month plan, with a family plan starting at USD 178 per month (no co-pays). 
 
 
 In June 2022 the company 
 <a href="https://sp-edge.com/updates/11233">
 acquired BlocHealth
 </a>
 for an undisclosed amount. The acquisition was carried out to improve SteadyMD&rsquo;s licensing and credentialing service, which will be available for both internal and partners&rsquo; clinicians. 
 
 
 Key customers and partnerships
 
 
 In October 2023, 98point6 partnered with 
 telehealth platform provider SteadyMD to provide an all-in-one virtual care offering to healthcare organizations. The partnership combined 98point6's cloud-based technology platform with SteadyMD's network of clinicians to help healthcare organizations lower costs, reduce burnout, and manage patient workloads. The collaboration aimed to create new revenue streams for healthcare organizations and increase provider efficiency while improving patient care.&nbsp;
 
 
 Funding and financials
 
 
 In May 2023, the company received an unspecified amount of venture funding from healthcare company AmerisourceBergen&rsquo;s venture funding arm, AB Health Venture Fund. 
 Post-funding, the companies partnered to co-create and pilot a TeleHealth solution that employs the &ldquo;Test to Treat&rdquo; business model, covering patients&rsquo; healthcare requirements at participating locations from the testing phase to dispensing treatment and medication. Through the partnership, patients gained access SteadyMD&rsquo;s platform at participating locations to receive Test to Treat options, including virtual consultations as needed.&nbsp;Participating pharmacies also used the pilot program to facilitate patients obtaining Covid-19 oral antiviral therapies as needed. The pilot program was rolled out across 130 retail pharmacies over the span of 12 weeks. &nbsp;
 
 
 
</div>

Managing employee health-related benefits

Health Benefits Platforms

<div>
 
 Sempre Health partners with leading health plan providers and pharmaceutical companies to enhance medication adherence and decrease out-of-pocket costs for patients. Through an approach that combines technology, behavioral science, dynamic pricing, and incentive alignment, Sempre Health encourages patients to make responsible health decisions, which in turn generates cost savings for insurers, care providers, and pharmaceutical companies. This model allows patients to benefit financially from their adherence to prescribed medication regimens, effectively improving health outcomes and making medications more affordable.
 
 
 Key customers and partnerships
 
 
 Sempre Health works directly with health plan providers and pharmaceutical companies to improve medication adherence and reduce out-of-pocket costs for patients. These benefits are extended to the consumers, who are the patients using prescribed medications. As of April 2019, Sempre Health had over 125,000 patients enrolled in its program and was on track to surpass 250,000 patients on the platform by the end of 2020.
 
 
 In November 2023, Sempre Health partnered with Organon, a global healthcare company, to launch an adherence program that aimed to motivate patients to adhere to prescriptions through a system of discounts based on timely refills. The program targets various factors contributing to non-adherence by incorporating elements like Sempre's auto-refill technology and personalized text messages.
 
 
 Funding and financials
 
 
 In September 2023, Sempre Health raised USD 20 million in additional funding. The funding round saw participation from three new investors, including Cencora Ventures and Echo Health Ventures, as well as existing investors such as Blue Venture Fund, UPMC Enterprises, and Industry Ventures. Sempre Health planned to use the new funding to speed up the expansion of its network of pharmaceutical manufacturers and health plan providers. With an outlook to expand into adjacent product areas, the company also aimed to significantly grow the number of patients benefiting from its solution.
 
 
 
</div>

Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost.  Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to $30.”  We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors.

SteadyMD is a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare in all 50 states. The company was founded in 2016 as a first-of-its-kind concierge primary care service, direct-to-consumer, and completely online. Today, SteadyMD enables its partners to scale their telehealth offerings quickly and efficiently nationwide by offering a 50-state licensed clinician workforce, clinical operations, legal and regulatory guidance, and world-class product and technology. SteadyMD’s carefully curated community of thousands of board-certified clinicians are passionate about improving access to high-quality care by utilizing state-of-the-art delivery modalities and serving patients across the entire care spectrum.

OneOncology is a partnership of oncologists and industry leading experts driving the future of community-based cancer care in the United States. They are more than just a network. They are a partnership of independent community oncologists working together as one to deliver comprehensive cancer care with compassion to our patients and their families, close to home. They empower oncologists to learn from their peers and leverage their collective experience to address the pressures facing community oncology today and to innovate for the future of cancer care delivery.

WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent, the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies. Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more. WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation.

TrakCel's proven technology integrates and orchestrates every aspect of Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.

Profarma has been engaged for 52 years in the distribution of pharmaceuticals, personal care products and cosmetics. The company provides medicines, personal care, health and beauty care, oncological, and dermatological products; and toiletries, vaccines, prostheses, and hormones in the South, Southeast, Northeast, and Center-West regions of Brazil.

Cencora, a company building on the legacy of AmerisourceBergen, is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We connect our pharmaceutical partners, providers, and patients to ensure that anyone can get the therapies they need, where and when they need them. We also help our partners bring their innovations to patients more efficiently to accelerate positive outcomes. Becoming Cencora has allowed us to combine all the companies and services of AmerisourceBergen. Now, as a unified and internationally inclusive brand, we’re continuing to invest in and focus on our core pharmaceutical distribution business, while also growing our platform of pharma and biopharma services to support pharmaceutical innovation and access. Our 46,000+ worldwide team members are shaping the future of healthcare through the power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen, now Cencora, is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $230 billion in annual revenue. Headquartered in Valley Forge, Pennsylvania, AmerisourceBergen has locations around the world. It handles about 20% of all of the pharmaceuticals sold and distributed throughout the U.S. They strive to take costs out of the healthcare system by using their scale and efficient operations to drive value for their customers. In addition to delivering pharmaceuticals on a just-in-time basis to tens of thousands of healthcare providers every day, they provide business support and consulting services to help their customers focus on their key strength—caring for patients. AmerisourceBergen is committed to the safety and security of the nation’s pharmaceutical supply chain. They purchase all branded and generic pharmaceuticals only directly from the product’s manufacturer, except in the rare instance that they are required to do otherwise either by the manufacturer or a government agency.

<div> Cencora (NYSE: COR) is a leading player in the pharmaceutical supply chain, providing distribution and other related services to pharmaceutical manufacturers and healthcare providers primarily in the US, dating back to 1871. Headquartered in Conshohocken, Pennsylvania, the modern incarnation of the company was founded under the name AmerisourceBergen Corporation in 2001, following the merger of Amerisource Health and Bergen Brunswig Corporations. In 2023, the company rebranded as Cencora, following several acquisitions since 2010. Notable among them was the acquisition of World Courier Group (which specializes in medical logistics) in 2012, MWI Veterinary Supplies in 2015 (which marked its entry into the Veterinary health industry), and Alliance Healthcare (a Europe-based distributor and supplier of pharmaceuticals and other healthcare products) in 2021, which significantly expanded its global presence. Cencora generated USD 262 billion in revenue in FY2023 (year ended 30 September). The company has two operating segments: US Healthcare Solutions and International Healthcare Solutions. Across both segments, the company is primarily involved in distributing a range of pharmaceuticals including brand-name, specialty, and generic drugs, over-the-counter products, and other healthcare supplies. It also offers specialized services including data analytics, management software and services, consulting and scientific affairs services, and integrated manufacturing and packaging solutions. US Healthcare Solutions also includes the animal health business, which provides pharmaceuticals, vaccines, parasiticides, and other products and services for both the companion and production animal markets.&nbsp; Cencora&rsquo;s largest market is the US, accounting for 90% of company revenue. The remainder is from international markets, predominantly Europe and Canada. As of Q1 FY2024, Cencora targets 10%&ndash;12% top-line growth and adjusted operating income increasing to 9%&ndash;11% in FY2024 in constant currency terms, slightly ahead of its long-term guidance of 5%&ndash;8% constant currency operating income growth. The company also plans to cut its Scope 1 and 2 greenhouse gas emissions by ~55% by FY2032 (baseline FY2019). </div>

Cencora

EDGE Insights

Digital Health (Q2 2023): Funding flow steady; first AI-drug enters Phase II clinical trials

Recent Updates

SteadyMD raises funding and partners with AmerisourceBergen to co-create and pilot telehealth solution

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless